Future studies using β-amyloid–based models, as well as combined tau–amyloid models, will be necessary to fully determine whether inhibition of colonic ASM by FIASMA is a shared neuroprotective tool across multiple pathological hallmarks of AD. Here, MAPT is linked to Alzheimer disease.